FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average I	hurdon								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					0.			., 00		Sumon	••••	.,,	0. 20.0								
1. Name and Address of Reporting Person* SAUNDERS JOHN					NI	2. Issuer Name <b>and</b> Ticker or Trading Symbol  NEUROCRINE BIOSCIENCES INC  NBIX ]										5. Relationship of Reporting Person(s) to Iss (Check all applicable) Director 10% Ov V Officer (give title Other (s					
(Last) 10555 SC	`	irst) ENTER DRIVE	(Middle) ER DRIVE					est Tran	ısact	tion (Moi	nth/E	Day/Year)		X Officer (give title Other (specify below)  Vice President Research (Chem)							
(Street) SAN DII			92121 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indiv ne) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(3)			Doriv	rativo	- So	riti	ios Ac		irod F	)icr	accod o	of or Do	noficia		Ownoo	<u> </u>				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D				action	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		tion	4. Securities Acquired (A Disposed Of (D) (Instr. 3,			5. Amou		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						$\perp$					v	Amount	(A) o (D)	Price		Transaction(s) (Instr. 3 and 4)				(11311. 4)	
Common Stock 11/12				2/2003	2003				A <sup>(2)</sup>		1,000	000 A S		.7	13,916			D			
		Т	able II -										, or Ben ble secu			wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (In:					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an Amount o Securities Underlyin Derivative (Instr. 3 a	f g Security	8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e O' S Fo Illy Di OI (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	e ercisable		xpiration ate	Title	Amount or Number of Shares							
Incentive Stock Option	\$5.375	11/12/2003			M <sup>(1)</sup>			1,000	03/	/02/2000	03	3/02/2009	Incentive Stock Option	1,000		\$5.375	15,725	5	D		

## **Explanation of Responses:**

- 1. Exercise of derivative security exempted pursuant to Rule 16b-3.
- 2. Holdings of 11/12/2003 exercise of underlying derivative security reported in Table II.

## Remarks:

Margaret Valeur-Jesen, by 11/14/2003 Power of Attorney

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.